|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, June 01, 2016 ) PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024
Summary
Bipolar disorder is a mental disorder characterized by periods of mania and depression. The frequency, severity, and pattern of these episodes can vary considerably over time and between individuals, making bipolar disorder one of the most challenging psychiatric disorders to manage. The bipolar disorder market is widely genericized, with additional key brands expected to face patent or data exclusivity expiries during the forecast period. The bipolar disorder market size is anticipated to contract significantly between 2014 and 2024, driven largely by the generic erosion of Otsukas Abilify, the highest selling bipolar disorder product in 2014. The uptake of novel atypical antipsychotic products will be a principal driver of growth over the forecast period, as these products offer clinical advantages that will drive strong uptake. However, sales of these agents will be limited by the continued utilization of established generic products. There are currently only two products in Phase III development, which indicates that bipolar disorder will remain a field of high unmet need during the forecast period.
Browse Market info, get a Sample PDF with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=725328
Highlights
Key Questions Answered
The bipolar disorder market is heavily genericized and many key players have chosen to deprioritize the indication. In light of this, what are the current clinical and environmental unmet needs? Will there be opportunities in this market for drug developers throughout the forecast period?
The current late-stage bipolar disorder pipeline is sparse, with only two products in Phase III development. What impact will these drugs have on the market? How will they affect the treatment algorithm for bipolar disorder? Will these drugs fulfil any of the unmet needs for bipolar disorder?
The management of bipolar disorder patients is challenging and a large number of variables can impact treatment outcomes. How does the diagnosis and treatment of bipolar disorder differ amongst the 8MM? Which treatment options are most commonly prescribed in each market, and how will prescribing patterns change over the forecast period?
Click to submit Query/ Enquiry: http://www.researchmoz.us/enquiry.php?type=E&repid=725328
Table of Contents
1 Table of Contents 12
1.1 List of Tables 17
1.2 List of Figures 24
2 Introduction 26
2.1 Catalyst 26
2.2 Related Reports 27
2.3 Upcoming Related Reports 27
3 Disease Overview 28
3.1 Etiology and Pathophysiology 28
3.1.1 Etiology 28
3.1.2 Pathophysiology 30
3.2 Classification 34
3.3 Symptoms 40
3.4 Prognosis 41
4 Epidemiology 43
4.1 Disease Background 43
4.2 Risk Factors and Comorbidities 43
4.3 Global Trends 45
4.4 Forecast Methodology 47
4.4.1 Sources Used 53
4.4.2 Sources Not Used 56
4.4.3 Forecast Assumptions and Methods 56
Contact Us:
Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
About ResearchMoz
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Researchmoz Global Pvt.Ltd
Researchmoz
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
